| |  Online-Ressource |
|---|
| Verfasst von: | Domingo-Domènech, Eva [VerfasserIn]  |
|---|
| | Boumendil, A. [VerfasserIn] |
|---|
| | Climent, F. [VerfasserIn] |
|---|
| | Socié, G. [VerfasserIn] |
|---|
| | Kroschinsky, F. [VerfasserIn] |
|---|
| | Finel, H. [VerfasserIn] |
|---|
| | Vandenbergue, E. [VerfasserIn] |
|---|
| | Nemet, D. [VerfasserIn] |
|---|
| | Stelljes, M. [VerfasserIn] |
|---|
| | Bittenbring, J. T. [VerfasserIn] |
|---|
| | Robinson, S. [VerfasserIn] |
|---|
| | Montoto, S. [VerfasserIn] |
|---|
| | Sureda, A. [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| Titel: | Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma |
|---|
| Titelzusatz: | a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
|---|
| Verf.angabe: | E. Domingo-Domènech, A. Boumendil, F. Climent, G. Socié, F. Kroschinsky, H. Finel, E. Vandenbergue, D. Nemet, M. Stelljes, J.T. Bittenbring, S. Robinson, S. Montoto, A. Sureda, P. Dreger on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | [2020] |
|---|
| Jahr des Originals: | 2019 |
|---|
| Umfang: | 8 S. |
|---|
| Illustrationen: | Diagramme |
|---|
| Fussnoten: | Published online: 6 November 2019 ; Gesehen am 16.04.2020 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 55(2020), 3, Seite 633-640 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a bridge to allo-HCT. Forty-four patients (24 females, median age 38 years) with sALCL were included. Twenty-three patients (52%) received BV before allo-HCT; BV-treated patients were more heavily pretreated (≥3 lines of therapy in 74% vs. 38%, p = 0.04). Twenty-three patients (52%) were in complete remission (CR) at allo-HCT. Three-year nonrelapse mortality and incidence of relapse (IR) after allo-HCT were 7% and 40%, respectively. With a median follow-up of 39 (12-69) months for survivors, 3-year progression-free survival (PFS) and overall survival were 53% and 74%, respectively. Univariate analysis showed that heavily pretreated patients and those not in CR had a higher IR and a lower PFS. The use of BV before transplant did not impact on any of the outcomes. Allo-HCT is a curative therapeutic strategy in a significant proportion of patients with relapsed/refractory sALCL; BV does not seem to modify transplant-related outcomes but might be able to render more patients candidates for this curative treatment. |
|---|
| DOI: | doi:10.1038/s41409-019-0732-9 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/s41409-019-0732-9 |
|---|
| | Volltext: https://www.nature.com/articles/s41409-019-0732-9 |
|---|
| | DOI: https://doi.org/10.1038/s41409-019-0732-9 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1694676544 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma / Domingo-Domènech, Eva [VerfasserIn]; [2020] (Online-Ressource)
